CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Financing Overview - CAMP4 Therapeutics has secured a private placement financing of up to $100 million, with an initial $50 million in upfront proceeds to fund the SYNGAP1 program and general corporate purposes [1][2] - The financing includes the issuance of 26,681,053 shares of common stock at $1.53 per share, along with additional shares and pre-funded warrants contingent on achieving specific milestones [2][4] Clinical Development - The funds will support the Phase 1/2 clinical trial for SYNGAP1-related disorders, expected to start in the second half of 2026 [1][2] - The company aims to develop a first-in-class treatment targeting gene expression to address genetic diseases [2][9] Management Changes - Doug Williams, Ph.D., has been appointed as Board Chair, and Dan Tardiff, Ph.D., has been elevated to Chief Scientific Officer [3][5] - The board has seen resignations and transitions, with a focus on enhancing leadership in drug discovery and development [3][5] Investor Participation - The financing is led by Coastlands Capital, with participation from both new and existing investors, including Janus Henderson Investors and Balyasny Asset Management [4] - Leerink Partners is acting as the lead placement agent, supported by other financial institutions [4] Company Background - CAMP4 Therapeutics focuses on developing RNA-targeting therapeutics to restore healthy protein levels for a range of genetic diseases [9] - The company utilizes its proprietary RAP Platform to identify and target regulatory RNAs associated with various genetic disorders [9]